Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients Meeting Abstract
| Authors: | Griesinger, F.; Kowanetz, M.; Zou, W.; Shames, D. S.; Cummings, C. A.; Rizvi, N. A.; Spira, A.; Frampton, G.; Leveque, V.; Flynn, S.; Mocci, S.; Shankar, G.; Funke, R.; Ballinger, M.; Waterkamp, D.; Chen, D. S.; Sandler, A.; Hampton, G.; Amler, L. C.; Hedge, P.; Hellmann, M. D. |
| Abstract Title: | Tumor mutation burden (TMB) is associated with improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 40 |
| Issue: | Suppl. 3 |
| Meeting Dates: | 2017 Sep 29-Oct 3 |
| Meeting Location: | Stuttgart, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2017-09-01 |
| Start Page: | 220 |
| End Page: | 221 |
| Language: | English |
| ACCESSION: | WOS:000411428400532 |
| PROVIDER: | wos |
| PUBMED: | 28934740 |
| DOI: | 10.1159/000479566 |
| Notes: | Meeting Abstract: V762 -- Source: Wos |
